Get to know our clinical trials
A phase 1/2 Study of Linvoseltamab in patients with relapsed or refractory sytemic light chain amyloidosis
THE STUDY IS RESEARCHING AN EXPERIMENTAL DRUG CALLED LINVOSELTAMAB LINVOSELTAMAB HAS BEEN STUDIED IN RESEARCH STUDY PARTICIPANTS WITH MULTIPLE MYELOMA, NOT IN RESEARCH STUDY PARTICIPANTS WITH SYSTEMIC AMYLOID LIGHT-CHAIN (AL) AMYLOIDOSIS. AL AMYLOIDOSIS IS USUALLY TREATED
Technical Summary
- A PHASE 1/2 STUDY OF LINVOSELTAMAB IN PATIENTS WITH RELAPSED OR REFRACTORY SYTEMIC LIGHT CHAIN AMYLOIDOSIS
- Code EudraCT: 2023-507809-34-00
- Protocol number: R5458-ONC-2274
- Promoter: Regeneron Pharmaceuticals, Inc.
- Molecule/Drug: LINVOSELTAMAB
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
More information about this clinical trial
Information offered by the Spanish Registry of Clinical Studies
- Summary
- Information
- Calendar
- Headquarters
- Drugs
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.